The commercialization of Invokana (canagliflozin) in France in 2026 is related to patent expiry and potential market entry for generic versions.
When can generic Invokana be sold in France?
The patent for canagliflozin, the active ingredient in Invokana, is set to expire in Europe in 2025 [1]. Following patent expiry, generic manufacturers can typically seek regulatory approval to market their versions of the drug [2]. This would allow for the introduction of generic canagliflozin in France and other European markets in 2026, provided regulatory hurdles are cleared [2].
What happens after Invokana's patent expires?
Once Invokana's patent protection ends, the market becomes open to competition from generic drug manufacturers [2]. These companies will produce their own versions of canagliflozin, which are expected to be significantly less expensive than the branded drug [3]. This increased competition can lead to lower prices for patients and healthcare systems [3].
Who makes generic versions of canagliflozin?
Companies specializing in generic pharmaceuticals are likely to develop and market canagliflozin after patent expiry [2]. While specific manufacturers for the French market in 2026 are not yet announced, major global generic drug producers will likely be involved [2].
What is the difference between Invokana and generic canagliflozin?
The primary difference between Invokana and generic canagliflozin will be the brand name and the price [3]. Generic versions must contain the same active ingredient, canagliflozin, and meet the same rigorous quality and efficacy standards set by regulatory authorities like the European Medicines Agency (EMA) [2]. They are designed to be therapeutically equivalent to the originator product [2].
How does canagliflozin work?
Canagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors [4]. It works by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be eliminated from the body through urine [4]. This mechanism helps to lower blood glucose levels in individuals with type 2 diabetes [4].
What is Invokana used for?
Invokana is prescribed to improve glycemic control in adults with type 2 diabetes mellitus [4]. It is also indicated for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease [4].
What are the risks associated with canagliflozin?
Potential risks and side effects associated with canagliflozin include urinary tract infections, increased urination, and genital yeast infections [4]. More serious, though less common, risks can include diabetic ketoacidosis, kidney problems, and lower limb amputations [4]. Patients should discuss all potential risks with their healthcare provider [4].
---
Sources:
[1] DrugPatentWatch.com, Canagliflozin Patent Expirations, https://drugpatentwatch.com/drug/canagliflozin/patent-expirations
[2] European Medicines Agency (EMA), Generic medicines, https://www.ema.europa.eu/en/human-regulatory/overview/generic-medicines
[3] U.S. Food & Drug Administration (FDA), Generic Drugs, https://www.fda.gov/drugs/generic-drugs
[4] Invokana Prescribing Information